Enterprise Therapeutics

Founded in 2014 and based in Brighton, UK, Enterprise Therapeutics Ltd. develops therapies for respiratory diseases such as cystic fibrosis, asthma, and chronic obstructive pulmonary disease (COPD). In January 2024, Enterprise Therapeutics Ltd.54 million post-money. Enterprise Therapeutics' primary focus is on developing drug candidates that address mucus congestion in respiratory diseases. Their lead product candidate, ETD001, is an inhaled epithelial sodium channel (ENaC) blocker designed to improve mucus clearance in the lungs. The company’s pipeline also includes other compounds targeting various mechanisms involved in mucus production and clearance for patients with severe respiratory conditions.

1. Series B

   Jan 26, 2024

   Amount

   $34M

   Investors

   Locked

2. Series B

   Apr 6, 2018

   Amount

   $32M

   Investors

   Locked

3. Series A

   Nov 4, 2016

   Amount

   $5M

   Investors

   Locked

4. Series A

   May 5, 2015

   Amount

   $3.7M

   Investors

   Locked

5. Series A

   Dec 1, 2014

   Amount

   $2.5M

   Investors

   Locked